Search research articles
Contact Us
Filters
Showing results (201-210 of 227) with videos related to
Page
of 23
Sort By:
Journal of the National Cancer Institute
|
December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Joseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
Haematologica
|
July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia
Scott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 9, 2013
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Stephen I Shibata, Vincent Chung, Timothy W Synold, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
Blood
|
March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
Kerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 227) with videos related to
Sort By:
Page
of 23
Journal of the National Cancer Institute
|
December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 1, 2008
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group
Joseph Gibbons, Merrill J Egorin, Ramesh K Ramanathan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 19, 2023
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Matthew Ingham, Jacob B Allred, Li Chen, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2009
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
Shivaani Kummar, Martin E Gutierrez, Erin R Gardner, et al.
Haematologica
|
July 28, 2011
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia
Scott H Kaufmann, Judith E Karp, Mark R Litzow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 9, 2013
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study
Stephen I Shibata, Vincent Chung, Timothy W Synold, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 29, 2020
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young K Chae, Fangxin Hong, Christos Vaklavas, et al.
Blood
|
March 23, 2021
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
Kerry A Rogers, Leslie A Andritsos, Lai Wei, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Page
of 23